The SCN3A gene plays a crucial role in the proper functioning of the brain's neurons. Mutations in this gene can lead to various neurological disorders, including a specific form of epilepsy known as focal SCN3A-related epilepsy. This condition is characterized by seizures that start in one area of the brain and can spread to other parts, potentially causing a range of symptoms from sensory disturbances to convulsions.
To diagnose this genetic condition accurately, DNA Labs UAE offers a specialized genetic test targeting the SCN3A gene. The test is designed to identify mutations in the SCN3A gene that are linked to the development of focal epilepsy. By analyzing a patient's DNA, the test can provide crucial information for the diagnosis, treatment planning, and management of the condition.
The cost of the SCN3A gene epilepsy focal SCN3A-related genetic test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis necessary to detect the presence of SCN3A mutations. Early and accurate diagnosis through this test can significantly impact the management of the condition, allowing for targeted treatment strategies that can improve the quality of life for individuals affected by SCN3A-related epilepsy.
The HCN2 gene, also known as the hyperpolarization-activated cyclic nucleotide-gated potassium channel 2, plays a significant role in the electrical activity of the heart and brain. Mutations in this gene have been linked to various neurological conditions, including certain forms of epilepsy. Epilepsy associated with the HCN2 gene involves a spectrum of seizure disorders, which can vary in severity and response to treatment.
To aid in the diagnosis and management of epilepsy potentially linked to the HCN2 gene, DNA Labs UAE offers a specialized genetic test. This test is designed to identify mutations in the HCN2 gene that may contribute to the development of epilepsy. By pinpointing the specific genetic alterations, healthcare providers can gain valuable insights into the condition, allowing for a more personalized approach to treatment and management.
The test is conducted with a sample of the patient's DNA, typically collected through a blood draw or a cheek swab. The sample is then analyzed in the laboratory using advanced genetic sequencing techniques to detect any mutations in the HCN2 gene.
The cost of the HCN2 related genetic test at DNA Labs UAE is 4400 AED. This investment can be pivotal for individuals and families seeking answers to unexplained seizure disorders, as it not only provides a clearer diagnosis but also opens the door to targeted treatment options and a better understanding of the condition's prognosis.
The SPATA5 gene epilepsy-hearing loss and mental retardation syndrome genetic test is a specialized diagnostic examination aimed at detecting mutations in the SPATA5 gene, which are associated with a rare, genetic disorder. This condition is characterized by a complex spectrum of symptoms, including epilepsy, hearing loss, and varying degrees of intellectual disability. The test involves analyzing the patient's DNA to identify any genetic variations that may indicate the presence of the syndrome, facilitating early diagnosis and intervention.
Performed at DNA Labs UAE, a leading facility in genetic testing, this test is designed for individuals who exhibit symptoms related to the syndrome or have a family history of genetic disorders. The cost of the test is set at 4400 AED, reflecting the comprehensive analysis and expertise required to accurately identify the SPATA5 gene mutations. Early detection through this genetic test can be crucial in managing symptoms, tailoring treatments, and improving the quality of life for those affected by this syndrome.
The GABRD gene epilepsy idiopathic generalized type 10 genetic test is a specialized diagnostic tool offered by DNA Labs UAE, aimed at identifying mutations in the GABRD gene, which have been linked to epilepsy. Idiopathic generalized epilepsy (IGE) encompasses a group of epilepsy syndromes that do not have a clear cause and are characterized by generalized seizures. The GABRD gene plays a crucial role in encoding a component of the GABA receptor, which is essential for inhibiting neurotransmission in the brain. Mutations in this gene can disrupt normal brain function, leading to the development of epilepsy.
This genetic test is particularly valuable for individuals who have been diagnosed with epilepsy but do not have an identifiable cause for their condition. By pinpointing specific genetic mutations, healthcare providers can gain a better understanding of the nature of the epilepsy, which can inform treatment decisions and potentially lead to more personalized and effective management strategies.
The test is conducted at DNA Labs UAE, a facility known for its advanced genetic testing services. The cost of the GABRD gene epilepsy idiopathic generalized type 10 genetic test is 4400 AED. This price reflects the comprehensive nature of the test, including the collection of a DNA sample, usually through a blood draw or cheek swab, the detailed analysis of the GABRD gene, and the provision of a report that interprets the results in the context of the patient's health and family history.
For individuals and families affected by idiopathic generalized epilepsy, this test represents a critical step towards understanding the genetic underpinnings of their condition and can guide more targeted and effective treatment approaches.
The CLCN2 gene epilepsy idiopathic generalized type 11 genetic test is a specialized diagnostic procedure designed to identify mutations in the CLCN2 gene, which have been associated with idiopathic generalized epilepsy type 11 (EIG11). This condition is a form of epilepsy characterized by various seizure types, including absence, myoclonic, and tonic-clonic seizures, without a clear cause. The CLCN2 gene plays a critical role in regulating chloride channels in neurons, and mutations can disrupt normal neuronal activity, leading to seizures.
This genetic test is crucial for individuals with a clinical diagnosis of idiopathic generalized epilepsy, as it can confirm the involvement of the CLCN2 gene mutation. The test involves collecting a DNA sample, typically through a blood draw or cheek swab, and analyzing it for specific mutations in the CLCN2 gene.
Conducted at DNA Labs UAE, a leading facility in genetic testing and diagnostics, the test offers a comprehensive analysis with reliable results. The cost of the test is set at 4400 AED, reflecting the advanced technology and expertise required to accurately identify the genetic variations associated with this form of epilepsy.
By confirming the genetic basis of the condition, the CLCN2 gene epilepsy idiopathic generalized type 11 genetic test can aid in the personalized management of the disorder, guiding treatment decisions and providing valuable information for family planning.
The SLC2A1 Gene Epilepsy idiopathic generalized type 12 Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify mutations in the SLC2A1 gene, which are associated with Epilepsy, idiopathic generalized type 12. This type of epilepsy is a genetic disorder characterized by seizures with no apparent cause, and it has been linked to variations in the SLC2A1 gene. The test plays a crucial role in the early detection and management of the condition, enabling healthcare providers to tailor treatment plans based on the genetic makeup of the individual.
Priced at 4400 AED, the test is conducted using a sample of the patient's DNA, typically extracted from a blood sample. The process involves advanced genetic sequencing techniques to meticulously analyze the SLC2A1 gene for specific mutations known to contribute to the development of epilepsy. The results from this test can provide valuable insights into the patient's condition, including the likelihood of developing epilepsy, potential response to treatments, and the risk of passing the condition on to future generations.
DNA Labs UAE is known for its state-of-the-art facilities and expertise in genetic testing, offering accurate and reliable results. The test is recommended for individuals with a family history of epilepsy or those who exhibit symptoms associated with the disorder, aiming to provide them with a clearer understanding of their condition and how best to manage it.
The EFHC1 gene plays a crucial role in the development of epilepsy, specifically juvenile absence epilepsy type 1 (JAE1). This condition is characterized by sudden, brief lapses in consciousness, often accompanied by subtle body movements. These episodes, known as absence seizures, typically begin in childhood or adolescence.
The genetic test for identifying mutations in the EFHC1 gene associated with JAE1 is a critical tool for diagnosis and management of the condition. Conducted at DNA Labs UAE, this test involves analyzing the patient's DNA to detect any abnormalities in the EFHC1 gene that may contribute to the development of epilepsy.
Understanding the genetic basis of JAE1 through this test can provide valuable insights into the most effective treatment plans, helping to manage or reduce the frequency of seizures. Additionally, it can offer important information for family planning purposes for those with a family history of epilepsy.
The cost of the EFHC1 gene epilepsy juvenile absence type 1 genetic test at DNA Labs UAE is 4400 AED. This investment in health can be a crucial step towards a more informed and personalized approach to managing juvenile absence epilepsy.
The KCNT1 gene epilepsy nocturnal frontal lobe genetic test is a specialized diagnostic procedure aimed at identifying mutations in the KCNT1 gene, which have been associated with a form of epilepsy that primarily manifests during the night, specifically affecting the frontal lobe of the brain. This condition is known for its challenging nature, as it often resists conventional epilepsy treatments, making the identification of the genetic underpinnings crucial for targeted management and therapeutic strategies.
Conducted at DNA Labs UAE, a facility renowned for its advanced genetic testing capabilities, the test involves collecting a DNA sample from the patient, usually through a blood draw or cheek swab. The sample is then analyzed using state-of-the-art genetic sequencing technologies to detect any abnormalities or mutations in the KCNT1 gene that may be contributing to the epilepsy.
The cost of the KCNT1 gene epilepsy nocturnal frontal lobe genetic test at DNA Labs UAE is 4400 AED. This price reflects the comprehensive nature of the test, encompassing the sophisticated laboratory techniques and expert analysis required to accurately identify mutations in the KCNT1 gene. For patients and families affected by this form of epilepsy, the test offers invaluable insights that can guide more personalized and effective treatment plans, potentially improving quality of life and disease outcomes.
The CHRNA4 Gene Epilepsy Nocturnal Frontal Lobe Type 1 Genetic Test is a specialized diagnostic procedure aimed at identifying mutations in the CHRNA4 gene, which have been linked to nocturnal frontal lobe epilepsy type 1 (ENFL1). This form of epilepsy is characterized by seizures that predominantly occur during sleep, affecting the frontal lobes of the brain. The CHRNA4 gene plays a crucial role in the regulation of neurotransmitter release in the brain, and mutations in this gene can disrupt normal neurological functions, leading to the development of epilepsy.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, this test is essential for individuals exhibiting symptoms of nocturnal frontal lobe epilepsy or those with a family history of the condition. By analyzing a sample of the patient's DNA, the test can detect specific genetic alterations in the CHRNA4 gene that are responsible for the disorder. This information is invaluable for accurate diagnosis, allowing healthcare providers to tailor treatment plans more effectively and offer genetic counseling to affected families.
The cost of the CHRNA4 Gene Epilepsy Nocturnal Frontal Lobe Type 1 Genetic Test at DNA Labs UAE is 4400 AED. While the price may seem significant, the test offers crucial insights into the genetic basis of the condition, enabling better management and understanding of the disease. It represents a critical step towards personalized medicine in the management of epilepsy, providing patients and their families with hope for more targeted and effective treatments.
The CHRNB2 gene is associated with a condition known as Epilepsy, nocturnal frontal lobe type 3 (ENFL3), a disorder characterized by seizures that often occur during sleep. These seizures can manifest as sudden arousals from sleep with motor activity, such as bicycling movements of the legs and hyperkinetic complex movements, often accompanied by vocalizations. This condition is linked to mutations in the CHRNB2 gene, which encodes a subunit of the neuronal nicotinic acetylcholine receptor. These receptors are critical for the proper conduction of signals in the brain, and mutations can disrupt normal neuronal activity, leading to seizures.
Genetic testing for mutations in the CHRNB2 gene can be crucial for the diagnosis and management of ENFL3. By identifying specific genetic alterations, healthcare providers can offer more personalized treatment plans and advice on managing the condition. Moreover, genetic testing can help to confirm a diagnosis when the clinical presentation is unclear and can also provide valuable information for family planning.
In the United Arab Emirates, DNA Labs UAE offers a genetic test specifically targeting the CHRNB2 gene to identify mutations associated with Epilepsy, nocturnal frontal lobe type 3. The cost of the test is 4400 AED. This specialized test is performed in a state-of-the-art laboratory setting by experienced professionals, ensuring high-quality, reliable results. By opting for this test, individuals and families affected by or at risk of ENFL3 can gain crucial insights into their condition, paving the way for informed decisions about treatment and management.
